Clark Estates Inc. NY Acquires New Shares in Indivior PLC (NASDAQ:INDV)

Clark Estates Inc. NY purchased a new stake in Indivior PLC (NASDAQ:INDV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 254,100 shares of the company's stock, valued at approximately $2,477,000. Clark Estates Inc. NY owned about 0.18% of Indivior at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of INDV. Cubist Systematic Strategies LLC increased its stake in Indivior by 32.0% in the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company's stock valued at $407,000 after purchasing an additional 6,121 shares during the period. Bank of New York Mellon Corp acquired a new position in Indivior in the 2nd quarter valued at about $188,000. VELA Investment Management LLC purchased a new stake in Indivior during the 2nd quarter valued at approximately $235,000. XTX Topco Ltd acquired a new stake in Indivior during the 2nd quarter worth approximately $249,000. Finally, Janus Henderson Group PLC grew its stake in shares of Indivior by 14.2% in the 1st quarter. Janus Henderson Group PLC now owns 440,121 shares of the company's stock valued at $9,424,000 after purchasing an additional 54,750 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Price Performance

Shares of INDV traded up $0.15 during mid-day trading on Wednesday, hitting $11.33. The company's stock had a trading volume of 521,448 shares, compared to its average volume of 527,005. The company has a current ratio of 0.83, a quick ratio of 0.65 and a debt-to-equity ratio of 23.50. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $23.22. The firm has a market capitalization of $1.56 billion, a P/E ratio of -279.43 and a beta of 0.70. The firm has a 50-day simple moving average of $9.53 and a 200 day simple moving average of $12.42.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The company had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. Analysts predict that Indivior PLC will post 1.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum dropped their price target on shares of Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, October 11th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.